Inovio Pharmaceuticals Net Income
| INO Stock | USD 1.66 0.10 6.41% |
As of the 8th of February, Inovio Pharmaceuticals retains the Standard Deviation of 5.14, risk adjusted performance of (0.07), and Market Risk Adjusted Performance of (0.58). Inovio Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Inovio Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 401.809 | Revenue | Earnings Share (2.72) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | -96.5 M | -101.4 M | |
| Net Loss | (4.54) | (4.77) | |
| Net Income Per E B T | 0.89 | 0.79 |
Inovio | Net Income | Build AI portfolio with Inovio Stock |
Evaluating Inovio Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Inovio Pharmaceuticals's fundamental strength.
Latest Inovio Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Inovio Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Inovio Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Inovio Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Inovio Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (107.25 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Inovio Net Income Regression Statistics
| Arithmetic Mean | (102,428,006) | |
| Coefficient Of Variation | (82.13) | |
| Mean Deviation | 58,476,540 | |
| Median | (96,528,713) | |
| Standard Deviation | 84,128,477 | |
| Sample Variance | 7077.6T | |
| Range | 297.1M | |
| R-Value | (0.62) | |
| Mean Square Error | 4649.7T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (10,325,051) | |
| Total Sum of Squares | 113241.6T |
Inovio Net Income History
Other Fundumenentals of Inovio Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Inovio Pharmaceuticals Net Income component correlations
Inovio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Net Income. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.72) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value - what Inovio Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Inovio Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inovio Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inovio Pharmaceuticals.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Inovio Pharmaceuticals on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Inovio Pharmaceuticals or generate 0.0% return on investment in Inovio Pharmaceuticals over 90 days. Inovio Pharmaceuticals is related to or competes with Acumen Pharmaceuticals, Opus Genetics, Agenus, Seer, Spero Therapeutics, Fate Therapeutics, and Seres Therapeutics. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of D... More
Inovio Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inovio Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inovio Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 36.52 | |||
| Value At Risk | (6.80) | |||
| Potential Upside | 6.41 |
Inovio Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inovio Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inovio Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Inovio Pharmaceuticals historical prices to predict the future Inovio Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.59) |
Inovio Pharmaceuticals February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.58) | |||
| Mean Deviation | 3.61 | |||
| Coefficient Of Variation | (1,070) | |||
| Standard Deviation | 5.14 | |||
| Variance | 26.43 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.59) | |||
| Maximum Drawdown | 36.52 | |||
| Value At Risk | (6.80) | |||
| Potential Upside | 6.41 | |||
| Skewness | (1.24) | |||
| Kurtosis | 6.41 |
Inovio Pharmaceuticals Backtested Returns
Inovio Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.0529, which attests that the entity had a -0.0529 % return per unit of risk over the last 3 months. Inovio Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Inovio Pharmaceuticals' Standard Deviation of 5.14, market risk adjusted performance of (0.58), and Risk Adjusted Performance of (0.07) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.84, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inovio Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Inovio Pharmaceuticals is expected to be smaller as well. At this point, Inovio Pharmaceuticals has a negative expected return of -0.28%. Please make sure to check out Inovio Pharmaceuticals' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Inovio Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.16 |
Very weak predictability
Inovio Pharmaceuticals has very weak predictability. Overlapping area represents the amount of predictability between Inovio Pharmaceuticals time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inovio Pharmaceuticals price movement. The serial correlation of 0.16 indicates that over 16.0% of current Inovio Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Inovio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Inovio Pharmaceuticals reported net income of (107.25 Million). This is 131.43% lower than that of the Biotechnology sector and 253.12% lower than that of the Health Care industry. The net income for all United States stocks is 118.78% higher than that of the company.
Inovio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in net income category among its peers.
Inovio Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Inovio Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Inovio Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inovio Pharmaceuticals' value.| Shares | Citadel Advisors Llc | 2025-06-30 | 169 K | Gsa Capital Partners Llp | 2025-06-30 | 163.3 K | Susquehanna International Group, Llp | 2025-06-30 | 151.3 K | Goldman Sachs Group Inc | 2025-06-30 | 136.8 K | Gmt Capital Corp | 2025-06-30 | 126.1 K | State Street Corp | 2025-06-30 | 123.6 K | Royal Bank Of Canada | 2025-06-30 | 122.3 K | Qube Research & Technologies | 2025-06-30 | 115.2 K | Fmr Inc | 2025-06-30 | 87.3 K | Vanguard Group Inc | 2025-06-30 | 2 M | Deep Track Capital, Lp | 2025-06-30 | 2 M |
Inovio Fundamentals
| Return On Equity | -3.28 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (492.03) % | ||||
| Current Valuation | 73.26 M | ||||
| Shares Outstanding | 68.7 M | ||||
| Shares Owned By Insiders | 0.39 % | ||||
| Shares Owned By Institutions | 38.77 % | ||||
| Number Of Shares Shorted | 11.69 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 4.58 X | ||||
| Price To Sales | 625.48 X | ||||
| Revenue | 217.76 K | ||||
| Gross Profit | (56.65 M) | ||||
| EBITDA | (103.95 M) | ||||
| Net Income | (107.25 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 11.87 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (104.08 M) | ||||
| Short Ratio | 5.35 X | ||||
| Earnings Per Share | (2.72) X | ||||
| Target Price | 7.63 | ||||
| Number Of Employees | 134 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 114.05 M | ||||
| Total Asset | 113.2 M | ||||
| Retained Earnings | (1.73 B) | ||||
| Working Capital | 62.5 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 113.2 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Inovio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Inovio Stock
Moving against Inovio Stock
| 0.66 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.54 | ENGN | enGene Holdings Common | PairCorr |
| 0.47 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.45 | DSGN | Design Therapeutics | PairCorr |
| 0.36 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.72) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value - what Inovio Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.